Imrie C W, McKay C J
Glasgow Royal Infirmary, Scotland, United Kingdom.
Gastroenterol Clin North Am. 1999 Sep;28(3):591-9, ix. doi: 10.1016/s0889-8553(05)70075-3.
For a 30-year period beginning in 1958, the general basis of medical therapy of acute pancreatitis had as its focus the provision of supplementary antiprotease therapy usually given intravenously. This concept was based on the belief that the body's natural antiprotease defense mechanism, which relies heavily on alpha 2-macroglobulin, together with alpha 1-antiprotease (alpha 1-antitrypsin), was inadequate to cope with the vast enzyme release that occurred with the onset of the more severe forms of the disease. This article examines recent studies and emerging theories on the medical therapy of acute pancreatitis.
从1958年开始的30年期间，急性胰腺炎药物治疗的总体基础重点在于提供通常通过静脉注射的补充抗蛋白酶疗法。这一概念基于这样一种信念，即人体主要依赖α2-巨球蛋白以及α1-抗蛋白酶（α1-抗胰蛋白酶）的天然抗蛋白酶防御机制，不足以应对更严重形式疾病发作时发生的大量酶释放。本文探讨了关于急性胰腺炎药物治疗的最新研究和新出现的理论。
